Merck & Co Inc

NYSE:MRK  
93.51
+1.42 (+1.54%)
4:37:35 PM EDT: $93.64 +0.13 (+0.14%)
Products, Strategic Combinations

HOOKIPA Collaborates With Merck To Evaluate HB-200 With Keytruda In Advanced Head And Neck Cancers

Published: 09/15/2021 11:10 GMT
Merck & Co Inc (MRK) - Hookipa Announces Collaboration With Merck, Kenilworth, Nj.
, USA to Evaluate Hb-200 With Keytruda in Patients With Advanced Head and Neck Cancers.
Hookipa Pharma Inc - Anticipates Initiating a Phase 2 Trial With Hb-200 in Combination With Keytruda in 2022.
Hookipa Pharma Inc - Additional Phase 2 Expansion Cohorts Are Also Planned to Start in Q1 2022.